These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 12086882)

  • 21. A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.
    Sausville EA
    J Natl Cancer Inst; 1999 Jan; 91(2):102-3. PubMed ID: 9923844
    [No Abstract]   [Full Text] [Related]  

  • 22. A hope for the future.
    Silver RT
    Cancer Invest; 2003 Jun; 21(3):486. PubMed ID: 12901295
    [No Abstract]   [Full Text] [Related]  

  • 23. Decrease of resistance to imatinib in leukaemia.
    Bakalova R; Zhelev Z; Ohba H
    Lancet; 2002 May; 359(9319):1776-7. PubMed ID: 12049890
    [No Abstract]   [Full Text] [Related]  

  • 24. Implications of signal transduction inhibition for the treatment of chronic myeloid leukemia.
    Sawyers CL
    Semin Hematol; 2001 Jul; 38(3 Suppl 8):1-2. PubMed ID: 11526594
    [No Abstract]   [Full Text] [Related]  

  • 25. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
    Druker BJ
    Oncogene; 2002 Dec; 21(56):8541-6. PubMed ID: 12476300
    [No Abstract]   [Full Text] [Related]  

  • 26. Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia.
    Knight GW; McLellan D
    Br J Biomed Sci; 2004; 61(2):103-11. PubMed ID: 15250677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
    Topaly J; Zeller WJ; Fruehauf S
    Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib and chronic-phase leukemias.
    Boros LG; Lee WN; Cascante M
    N Engl J Med; 2002 Jul; 347(1):67-8. PubMed ID: 12097546
    [No Abstract]   [Full Text] [Related]  

  • 29. Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.
    Topaly J; Schad M; Laufs S; Melo JV; Zeller WJ; Fruehauf S
    Br J Haematol; 2003 May; 121(4):672-3. PubMed ID: 12752112
    [No Abstract]   [Full Text] [Related]  

  • 30. STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology?
    Gambacorti C
    Tumori; 2001; 87(6):S10-2. PubMed ID: 11989608
    [No Abstract]   [Full Text] [Related]  

  • 31. First-line therapy for CML: nilotinib comes of age.
    Davies J
    Lancet Oncol; 2011 Sep; 12(9):826-7. PubMed ID: 21856227
    [No Abstract]   [Full Text] [Related]  

  • 32. [Chronic myeloid leukemia and imatinib mesylate therapy].
    Chrobák L
    Vnitr Lek; 2004 Jan; 50(1):10-2. PubMed ID: 15015223
    [No Abstract]   [Full Text] [Related]  

  • 33. From the Food and Drug Administration.
    Schwetz BA
    JAMA; 2001 Jul; 286(1):35. PubMed ID: 11434814
    [No Abstract]   [Full Text] [Related]  

  • 34. STI571 (imatinib mesylate): the tale of a targeted therapy.
    Thambi P; Sausville EA
    Anticancer Drugs; 2002 Feb; 13(2):111-4. PubMed ID: 11901302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.
    Barthe C; Gharbi MJ; Lagarde V; Chollet C; Cony-Makhoul P; Reiffers J; Goldman JM; Melo JV; Mahon FX
    Br J Haematol; 2002 Oct; 119(1):109-11. PubMed ID: 12358910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapy.
    Press RD
    Oncologist; 2010; 15(7):744-9. PubMed ID: 20566700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
    Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
    Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer treatment. New drugs, new hope.
    Harv Health Lett; 2001 Jul; 26(9):1-3. PubMed ID: 11511447
    [No Abstract]   [Full Text] [Related]  

  • 39. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
    Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
    Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Chronic myeloid leukemia and tyrosine kinase inhibitors].
    Mahon FX
    Rev Med Interne; 2001 Sep; 22(9):894-9. PubMed ID: 11599196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.